Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

310 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Outcome of children and adolescents with central nervous system tumors in phase I trials.
Carceller F, Bautista F, Jiménez I, Hladun-Álvaro R, Giraud C, Bergamaschi L, Dandapani M, Aerts I, Doz F, Frappaz D, Casanova M, Morland B, Hargrave DR, Vassal G, Pearson ADJ, Geoerger B, Moreno L, Marshall LV. Carceller F, et al. Among authors: frappaz d. J Neurooncol. 2018 Mar;137(1):83-92. doi: 10.1007/s11060-017-2698-z. Epub 2017 Dec 13. J Neurooncol. 2018. PMID: 29236237
Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors.
Geoerger B, Hargrave D, Thomas F, Ndiaye A, Frappaz D, Andreiuolo F, Varlet P, Aerts I, Riccardi R, Jaspan T, Chatelut E, Le Deley MC, Paoletti X, Saint-Rose C, Leblond P, Morland B, Gentet JC, Méresse V, Vassal G; ITCC (Innovative Therapies for Children with Cancer) European Consortium. Geoerger B, et al. Among authors: frappaz d. Neuro Oncol. 2011 Jan;13(1):109-18. doi: 10.1093/neuonc/noq141. Epub 2010 Oct 25. Neuro Oncol. 2011. PMID: 20974795 Free PMC article. Clinical Trial.
Prognostic factors of overall survival in children and adolescents enrolled in dose-finding trials in Europe: An Innovative Therapies for Children with Cancer study.
Carceller F, Bautista FJ, Jiménez I, Hladun-Álvaro R, Giraud C, Bergamaschi L, Dandapani M, Aerts I, Doz F, Frappaz D, Casanova M, Morland B, Hargrave DR, Marshall LV, Vassal G, Pearson AD, Geoerger B, Moreno L. Carceller F, et al. Among authors: frappaz d. Eur J Cancer. 2016 Nov;67:130-140. doi: 10.1016/j.ejca.2016.08.008. Epub 2016 Sep 21. Eur J Cancer. 2016. PMID: 27662616
A phase II single-arm study of irinotecan in combination with temozolomide (TEMIRI) in children with newly diagnosed high grade glioma: a joint ITCC and SIOPE-brain tumour study.
Hargrave D, Geoerger B, Frappaz D, Pietsch T, Gesner L, Cisar L, Breazna A, Dorman A, Cruz-Martinez O, Fuster JL, Rialland X, Icher C, Leblond P, Ashley D, Perilongo G, Elliott M, English M, Clausen N, Grill J. Hargrave D, et al. Among authors: frappaz d. J Neurooncol. 2013 May;113(1):127-34. doi: 10.1007/s11060-013-1098-2. Epub 2013 Mar 4. J Neurooncol. 2013. PMID: 23459995 Clinical Trial.
Phase II study of temozolomide and topotecan (TOTEM) in children with relapsed or refractory extracranial and central nervous system tumors including medulloblastoma with post hoc Bayesian analysis: A European ITCC study.
Le Teuff G, Castaneda-Heredia A, Dufour C, Jaspan T, Calmon R, Devos A, McHugh K, Leblond P, Frappaz D, Aerts I, Zwaan CM, Ducassou S, Chastagner P, Verschuur A, Corradini N, Casanova M, Rubie H, Riccardi R, Le Deley MC, Vassal G, Geoerger B; European consortium Innovative Therapies for Children with Cancer (ITCC). Le Teuff G, et al. Among authors: frappaz d. Pediatr Blood Cancer. 2020 Jan;67(1):e28032. doi: 10.1002/pbc.28032. Epub 2019 Oct 8. Pediatr Blood Cancer. 2020. PMID: 31595663 Clinical Trial.
Reduced-dose craniospinal irradiation is feasible for standard-risk adult medulloblastoma patients.
Massimino M, Sunyach MP, Barretta F, Gandola L, Garegnani A, Pecori E, Spreafico F, Bonneville-Levard A, Meyronet D, Mottolese C, Boschetti L, Biassoni V, Schiavello E, Giussani C, Carrabba G, Diletto B, Pallotti F, Stefini R, Ferrari A, Terenziani M, Casanova M, Luksch R, Meazza C, Podda M, Chiaravalli S, Puma N, Bergamaschi L, Morosi C, Calareso G, Giangaspero F, Antonelli M, Buttarelli FR, Frappaz D. Massimino M, et al. Among authors: frappaz d. J Neurooncol. 2020 Jul;148(3):619-628. doi: 10.1007/s11060-020-03564-y. Epub 2020 Jun 21. J Neurooncol. 2020. PMID: 32567042
Phase 1 dose-escalation and pharmacokinetic study of regorafenib in paediatric patients with recurrent or refractory solid malignancies.
Geoerger B, Morland B, Jiménez I, Frappaz D, Pearson ADJ, Vassal G, Maeda P, Kincaide J, Mueller U, Schlief S, Teufel M, Ploeger BA, Cleton A, Agostinho AC, Marshall LV. Geoerger B, et al. Among authors: frappaz d. Eur J Cancer. 2021 Aug;153:142-152. doi: 10.1016/j.ejca.2021.05.023. Epub 2021 Jun 20. Eur J Cancer. 2021. PMID: 34157616 Free article. Clinical Trial.
Phase II study of gemcitabine combined with oxaliplatin in relapsed or refractory paediatric solid malignancies: An innovative therapy for children with Cancer European Consortium Study.
Geoerger B, Chisholm J, Le Deley MC, Gentet JC, Zwaan CM, Dias N, Jaspan T, Mc Hugh K, Couanet D, Hain S, Devos A, Riccardi R, Cesare C, Boos J, Frappaz D, Leblond P, Aerts I, Vassal G; European Consortium Innovative Therapies for Children with Cancer (ITCC). Geoerger B, et al. Among authors: frappaz d. Eur J Cancer. 2011 Jan;47(2):230-8. doi: 10.1016/j.ejca.2010.09.015. Epub 2010 Oct 11. Eur J Cancer. 2011. PMID: 20943374 Clinical Trial.
310 results